Critical illness neuromuscular abnormalities

Critical Care Clinics

Volumn 18, Issue 3, 2002, Pages 553-568

  Lorin, Scott ^a   Nierman, David M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN; NERVE GROWTH FACTOR;

ARTIFICIAL VENTILATION; CHRONIC DISEASE; CHRONIC PATIENT; CLINICAL EXAMINATION; CRITICAL ILLNESS; EARLY DIAGNOSIS; ELECTROPHYSIOLOGY; GLUCOSE BLOOD LEVEL; HUMAN; IATROGENIC DISEASE; INFLAMMATION; MORTALITY; NEUROMUSCULAR DISEASE; NUTRITIONAL SUPPORT; PERIPHERAL NERVOUS SYSTEM; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SOCIAL ASPECT;

DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROMUSCULAR JUNCTION DISEASES; PHRENIC NERVE; POLYNEUROPATHIES; PROGNOSIS; RESPIRATION, ARTIFICIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VENTILATOR WEANING;

EID: 0036309855     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(02)00003-9     Document Type: Review

References (88)

1. Neuromuscular causes of prolonged ventilator dependency
2. Neurologic complications of critical medical illnesses
3. Prevalence and severity of neurologic dysfunction in critically ill patients. Influence on need for continued mechanical ventilation
4. The electrophysiologic investigation of respiratory paralysis in critically ill patients
5. Reversible generalized paresis following hypotension: A new neurologic entity
6. Prolonged respiratory insufficiency due to acute motor neuropathy; A new syndrome?
7. Patterns of neurophysiological abnormality in prolonged critical illness
8. Causes of neuromuscular weakness in the intensive care unit: A study of ninety-two patients
9. Critical illness myopathy and neuropathy
10. Neuromuscular disorders associated with failure to wean from the ventilator
11. Acquired neuromuscular disorders in critically ill patients: A systematic review
12. Critical illness polyneuropathy: Risk factors and clinical consequences. A cohort study in septic patients
13. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis
14. Incidence and onset of critical illness polyneuropathy in patients with septic shock
15. Critically ill polyneuropathy: Electrophysiological studies and differentiation from Guillain-Barre syndrome
16. Critical illness polyneuropathy. A review of the literature, definition and pathophysiology
17. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure
18. Sepsis and the systemic inflammatory response syndrome: Neuromuscular manifestations
19. Sepsis and catecholamine support are the major risk factors for critical illness polyneuropathy after open heart surgery'
20. Tumor necrosis factor and interleukin-6 in critical illness polyneuromyopathy
21. Critical illness polyneuropathy and myopathy (CIPNM): Evidence for local immune activation by cytokine-expression in the muscle tissue
22. Critical illness polyneuropathy: Clinical findings and cell culture assay of neurotoxicity assessed by a prospective study
23. Intensive insulin therapy in critically ill patients
24. Polyneuropathies in critically ill patients: A prospective evaluation
25. Risk factors for the development of polyneuropathy and myopathy in critically ill patients
26. Predominant involvement of motor fibres in patients with critical illness polyneuropathy
27. Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator
28. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation
29. Round table conference on ventilatory failure, Brussels, Belgium, March 16-18, 1991
30. Peripheral nerve function in sepsis and multiple organ failure
31. Motor neuropathy in a patient with Legionnaires' disease
32. Peripheral neuropathy-an unusal complication of meningococcemia
33. Response of man to endotoxin
34. Polyradiculoneuritis and Mycoplasma pneumoniae infection
35. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure
36. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis
37. Critical illness polyneuropathy: A summary of the literature on rehabilitation outcome
38. Critical illness polyneuromyopathy after artificial respiration
39. Critical illness polyneuropathy. A 2-year follow-up study in 19 severe cases
40. Long-term outcome of critical illness polyneuropathy
41. Critical illness polyneuropathy: A new iatrogenically induced syndrome after cardiac surgery?
42. Concomitant cardiac and pulmonary operation. Pulmonary mechanics and outcome of phrenic nerve injury
43. Left lower lobe atelectasis and consolidation following cardiac surgery: The effect of topical cooling on the phrenic nerve
44. Elevated hemidiaphragm after cardiac operations: Incidence, prognosis, and relationship to the use of topical ice slush
45. Phrenic nerve and diaphragm function following open heart surgery: A prospective study with and without topical hypothermia
46. Incidence and aetiology of a raised hemidiaphragm after cardiopulmonary bypass
47. Effects of temperature on phrenic nerve and diaphragmatic function during cardiac surgery
48. Phrenic nerve function and its relationship to atelectasis after coronary artery bypass surgery
49. Phrenic nerve injury. A prospective study
50. Diabetes mellitus, internal thoracic artery grafting, and risk of an elevated hemidiaphragm after coronary artery bypass surgery
51. Technology under Medicare diagnosis-related groups prospective payment. Implications for medical intensive care
52. Incidence and natural history of phrenic neuropathy occurring during open heart surgery
53. Phrenic nerve injury in infants and children undergoing cardiac surgery
54. Phrenic nerve injury after coronary artery bypass grafting: Will it go away?
55. Delay of extubation in neonates and children after cardiac surgery: Impact of ventilator-associated pneumonia
56. Recovery after unilateral phrenic injury associated with coronary artcry rcvascularization
57. Myopathy in critically ill patients
58. Acute type II myofiber atrophy in critical illness
59. Acute myopathy after liver transplantation
60. Acute myopathy and neuropathy in status asthmaticus: Case report and literature review
61. Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both
62. Severe myopathy after status asthmaticus
63. Necrotizing myopathy in critically-ill patients
64. Myopathy in severe asthma
65. Complications associated with sedative and neuromuscular blocking drugs in critically ill patients
66. Prolonged muscle weakness after neuromuscular blockade in the intensive care unit
67. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation
68. Vecuronium-associated axonal motor neuropathy: A variant of critical illness polyneuropathy?
69. Prolonged weakness after long-term infusion of vecuronium bromide
70. Prolonged neuromuscular blockade with atracurium
71. Prolonged paralysis after treatment with neuromuscular junction blocking agents
72. Muscle strength following anaesthesia with atracurium and pancuronium
73. Persistent paralysis in critically ill patients after long-term administration of vecuronium
74. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients
75. Does vecumnium accumulate in the renal transplant patient?
76. Clinical and electrophysiological findings in critical illness polyneuropathy
77. A nerve growth stimulating factor isolated from sarcoma 37 and 180
78. Neurotrophic factors in the treatment of neurotoxicity: An overview
79. Nerve growth factor signaling, neuroprotection, and neural repair
80. Peripheral neuropathies and neurotrophic factors: Animal models and clinical perspectives
81. Development of recombinant human nerve growth factor (rhNGF) as a treatment for peripheral neuropathic disease
82. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy
83. The use of insulin-like growth factor I in the prevention of vincristine neuropathy in mice
84. Nerve growth factor prevents experimental cisplatin neuropathy
85. Nerve growth factor prevents toxic neuropathy in mice
86. Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766
87. Nerve growth factor in neurological and non-neurological diseases: Basic findings and emerging pharmacological prospectives
88. Critical illness polyneuropathy: Clinical findings and outcomes of a frequent cause of neuromuscular weaning failure